Sante Manufacturing’s OTC drugs have significant CGMP violations, including missing identity testing for a high-risk component and inadequate process validation and quality oversight.
What happened
FDA reviewed records and other information that Sante submitted after FDA’s July 7, 2025 request under section 704(a)(4) of the FD&C Act. FDA said the records showed significant CGMP violations for finished drugs: the firm did not adequately test each incoming lot of a high-risk component for identity or establish the reliability of supplier tests, did not adequately qualify or monitor a system used to produce a component or show an appropriate process validation program, and its quality unit did not provide adequate oversight. FDA placed all drugs and drug products offered for import from the firm on Import Alert 66-40 on April 27, 2026.
What FDA found
FDA said Sante did not test each incoming lot of a high-risk component to verify its identity and did not establish the reliability of the supplier’s test results.
21 CFR 211.84(d)(1) and 211.84(d)(2)FDA said Sante did not adequately qualify or monitor a system used to produce a component, and did not show an appropriate process validation program.
21 CFR 211.100(a)FDA said the quality control unit did not ensure an adequate stability testing program or validate analytical methods, so it did not adequately oversee CGMP compliance and specifications.
21 CFR 211.22; 21 CFR 211.166(a); 21 CFR 211.160(b)
What FDA wants
Respond in writing within 15 working days with what you have done to correct the violations and prevent recurrence, and state reasons and a completion schedule if you cannot finish in that time. FDA also asks for commitments to provide certain (b)(4) test results within 30 calendar days and detailed plans for risk assessment, component testing, process validation, and quality-unit remediation.
Who should pay attention
- companies that buy OTC drugs from this Canadian manufacturer
- brands using contract manufacturers for OTC drug products
- importers and suppliers of high-risk drug components
This is a summary. Read the original letter on fda.gov.